Teva, Krka d.d., Lupin, Mylan, Servier, Alliance Healthcare (Distribution) Ltd. cardiovascular news

The European Commission sent a statement of objections to Servier and the generic competitors regarding an investigation into suspected violations of EU antitrust laws relating to Servier's cardiovascular drug Coversyl perindopril. The EC alleged that Servier paid Alliance (formerly Unichem Ltd.), Mylan, Teva, Krka and Lupin to enter into patent settlement agreements in which they agreed not to enter the market with their cheaper generic products and/or not to further challenge the validity of Servier's patents. The commission also alleges that Servier acquired competing technologies as part of a comprehensive strategy to delay generic entry. The EC said perindopril is about to go off patent protection. ...